NASDAQ
28.02.25
21:58 Uhr
1,620 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Milestone Pharmaceuticals' (MIST) Buy Rating Reiterated at HC Wainwright | 2 | MarketBeat | ||
| Di | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 9 | SEC Filings | ||
| 19.02. | Milestone Pharmaceuticals sichert sich wichtiges Patent für CARDAMYST | 6 | Investing.com Deutsch | ||
| MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 19.02. | Milestone Pharmaceuticals secures key patent for CARDAMYST | 2 | Investing.com | ||
| 11.02. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 | 1 | GlobeNewswire (USA) | ||
| 28.01. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC | 188 | GlobeNewswire (Europe) | - PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT... ► Artikel lesen | |
| 07.01. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 91 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards... ► Artikel lesen | |
| 12.11.24 | Milestone Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 185 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and... ► Artikel lesen | |
| 12.11.24 | Milestone Pharmaceuticals Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10.24 | Milestone Pharmaceuticals maintains Buy rating from TD Cowen | 4 | Investing.com | ||
| 14.10.24 | Wainwright maintains Buy rating on Milestone Pharma stock | 5 | Investing.com | ||
| 06.09.24 | Milestone Pharmaceuticals Inc.: Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China | 159 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 04.09.24 | Milestone Pharmaceuticals welcomes new board member Joseph Papa | 1 | Investing.com | ||
| 04.09.24 | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 08.08.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 132 | GlobeNewswire (Europe) | - NDA for CARDAMYST in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 - Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 - Stuart Duty and Andrew Saik Appointed... ► Artikel lesen | |
| 29.05.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST | 281 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 13.05.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 213 | GlobeNewswire (Europe) | - NDA for etripamil in PSVT resubmitted in 1Q 2024- Cash resources as of March 31, 2024 expected to fund operations into 2026- Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR... ► Artikel lesen | |
| 08.04.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting | 183 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 23,390 | +2,99 % | DAX nach Wahl höher: Ifo-Geschäftsklima, Rheinmetall, BASF, Bayer, Siemens Energy, Just Eat ... | Dem DAX hat es am Freitag, am letzten Handelstag der Woche vor den Bundestagswahlen, an Schwung gefehlt. Er ging mit einem Minus von 0,1 Prozent bei 22.287,56 Zählern aus dem Handel. Nachdem nun das... ► Artikel lesen | |
| PFIZER | 25,215 | -1,02 % | Pfizer? Das ist die heißeste Biotech-Aktie 2025 | Die Pharmaindustrie steht vor einer Übernahmeoffensive, darauf deuten immer mehr Anzeichen hin. Ablaufende Patente und löchrige Pipelines zwingen große Player wie Pfizer zu Akquisitionen. Profiteure... ► Artikel lesen | |
| GILEAD SCIENCES | 109,00 | -1,09 % | MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy in Advanced Breast Cancer | WIN-B (NCT06612203) is a Phase Ib/II, multi-center investigator-initiated trial, evaluating the safety and preliminary efficacy of combining Debiopharm's selective WEE1 inhibitor, Debio 0123 and... ► Artikel lesen | |
| MERCK & CO | 88,30 | -0,67 % | Neue Brustkrebs-Kampagne von MSD Sharp & Dohme: Aufklären, Mut machen und Patient:innen ab der Diagnose begleiten | München (ots) - Anlässlich des heutigen Triple-Negative Breast Cancer-Tages stellt MSD Sharp & Dohme GmbH die neue Awareness-Kampagne "Diagnose Brustkrebs - was nun?" vor. Sie zeigt den Weg der Brustkrebs-Patientin... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 459,00 | -0,72 % | Vertex Aktie: Strahlende Aussichten entwickeln sich! | Führende Köpfe des Biotechnologieunternehmens Vertex Pharmaceuticals Inc. haben kürzlich Aktien im erheblichen Umfang verkauft. Die Transaktion erfolgte zu einem Zeitpunkt, an dem die Vertex-Aktie eine... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 5,926 | -1,82 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 12,600 | +2,02 % | Assembly Biosciences, Inc.: Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus | - Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 - - Biomarker of ABI-6250 target engagement, serum bile acids... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 6,430 | 0,00 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| ROCKET LAB USA | 20,300 | +2,78 % | Rocket Lab Stock: Why I'm Buying More | ||
| NEWRON PHARMACEUTICALS | 10,620 | +0,19 % | Community-Rückblick: wO-User zu Newron Pharma nach Südkorea Deal: "2028 ist die Firma Geschichte..." | © Foto: ChatGPTDie Diskussion um Newron Pharma flammte erneut auf, nachdem die italienische Biotechfirma am 09.01. die Kooperation mit "Myung In Pharm", zwecks Vertrieb des Hoffnungsmittels Evenamide... ► Artikel lesen | |
| OPKO HEALTH | 1,674 | -0,50 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results | MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 117,00 | +6,36 % | ROUNDUP: Ligand Pharma Slips To Loss In Q4; Confirms FY25 Outlook | WASHINGTON (dpa-AFX) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal... ► Artikel lesen | |
| ALTIMMUNE | 6,182 | -3,78 % | Altimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.01 EPS | ||
| JAZZ PHARMACEUTICALS | 136,55 | -1,27 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance | - Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 -- Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 -- Oncology revenues grew... ► Artikel lesen | |
| ROYALTY PHARMA | 32,650 | +0,71 % | Dividendenbekanntmachungen (21.02.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN AUSTRALIA EQUITY FUND INC US0030111035 0,12 USD 0,1143 EUR ABRDN JAPAN EQUITY FUND INC US00306J1097 0,11 USD 0,1047 EUR ANGEL... ► Artikel lesen |
Das Unternehmen MILESTONE PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MILESTONE PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
